Filing Flows › iBio (IBIO) › Q4 FY25
iBio (IBIO) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Sep 5, 2025
iBio (IBIO) reported revenue of $200K for the fourth quarter fiscal 2025 (Q4 FY25), +14% from a year earlier.
iBio, Q4 FY25: revenue $200K (+14% year over year), net loss $5.2M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $200K | — | +14% |
| Operating profit | −$5.2M | — | — |
| Net earnings | −$5.2M | — | — |
| Operating cash flow | −$4.6M | — | — |
What changed
Revenue was $200K in Q4 FY25, up 14% year over year.
Operating costs exceeded revenue by $5.2M, an operating margin of -2599.0%. Total costs grew 51% against revenue growth of 14%. The fastest-growing cost line was Research & development (+183%). The quarter ended with a net loss of $5.2M.
Operating cash flow was −$4.6M. Non-cash charges added back $126K of depreciation and amortization and $270K of share-based compensation. Capital expenditures of $1K exceeded it, leaving free cash flow of −$4.6M.
Questions
What was iBio's revenue in the fourth quarter fiscal 2025?
iBio (IBIO) reported revenue of $200K for the fourth quarter fiscal 2025 (Q4 FY25), +14% from a year earlier.
Source: iBio 10-K on SEC EDGAR.